

**MyMD Pharmaceuticals, Inc.**  
**855 N. Wolfe Street, Suite 623**  
**Baltimore, MD 21205**

May 10, 2021

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Securities and Exchange Commission  
Washington, D.C. 20549

Attention: Ms. Margaret Schwartz  
Mr. Joe McCann

Re: MyMD Pharmaceuticals, Inc., f/k/a Akers Biosciences, Inc.  
Registration Statement on Form S-3  
Originally filed on March 25, 2021, as amended on April 28, 2021  
File No. 333-254698 (the "**Registration Statement**")  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the "**Commission**") under the Securities Act of 1933, as amended, MyMD Pharmaceuticals, Inc. (f/k/a Akers Biosciences, Inc., the "**Company**") hereby respectfully requests acceleration of the effective date of the Registration Statement, as amended, so that it may become effective at 4:00 p.m., Eastern Time, on May 11, 2021, or as soon thereafter as practicable.

Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.

Very truly yours,

MYMD PHARMACEUTICALS, INC.

By: /s/ Chris Chapman

Chris Chapman  
President, Chief Medical Officer, and Director

cc: Rick A. Werner, Esq., Haynes and Boone, LLP

---